New drug duo aims to tackle returning cervical cancer
NCT ID NCT04068753
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing whether combining two drugs, niraparib and dostarlimab, can help shrink or control cervical cancer that has come back or spread. About 66 women with recurrent or progressive cervical cancer will receive the treatment. The goal is to see how many respond and how safe the combination is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- niraparib and dostarlimab
- What this could lead to
- If successful, this combination could offer a new treatment option to help control recurrent or progressive cervical cancer.
- What could go wrong
- This is a Phase 2 trial with only 66 participants, so results are preliminary. The combination may not work for everyone and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE CERVIX CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Louisiana State University Health Science Center
New Orleans, Louisiana, 70112, United States
-
Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22903, United States